COMMUNIQUÉS West-GlobeNewswire

Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
31/03/2025
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease (AKD); Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in H2 2025 Raised $140 Million in [...]
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
31/03/2025
Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical company advancing a [...]
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
31/03/2025
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025 Positive NPM-139 ( [...]
Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV
31/03/2025
MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris ® or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission
31/03/2025
NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated [...]
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
31/03/2025
- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data [...]
Atavistik Bio Announces Appointment of William Sellers, M.D. to its Scientific Advisory Board
31/03/2025
Dr. William Sellers is a leading cancer researcher who currently serves as a Core Institute member and Director of the cancer program at the Broad Institute and a professor of medicine at Dana-Farber Cancer Institute [...]
Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives
31/03/2025
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at [...]
Venus Concept Announces Fourth Quarter and Fiscal Year 2024 Financial Results
31/03/2025
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and twelve months [...]
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
31/03/2025
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will [...]
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
31/03/2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence [...]
Remix Therapeutics to Present at Stifel 2025 Virtual Targeted Oncology Forum
31/03/2025
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers [...]
TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
WALTHAM, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies [...]
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery
31/03/2025
The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage [...]
ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights
31/03/2025
Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline [...]
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
31/03/2025
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of [...]
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
31/03/2025
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies [...]
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
31/03/2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical [...]
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
31/03/2025
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses [...]

Pages